Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Table: The Combatants


All three of America's top cloning companies anticipate windfalls in licensing technology, but their strategies differ in substantial respects

GERON

BUSINESS: Research into the enzyme telomerase as an anticancer agent; study of embryonic stem cells for treating disease; licensing of cloning technology

REVENUES: $3.6 million

ADVANCED CELL TECHNOLOGY

BUSINESS: Cloning animals such as dairy cows; researching the cloning of human embryos for stem-cell production; licensing of cloning technology

REVENUES: $2 million

INFIGEN

BUSINESS: Cloning of cows and pigs; researching animal cloning for production of human therapeutic products

REVENUES: Not disclosed


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus